Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan
· Delayed Price · Currency is TWD 611.00
+10.00 (1.66%)
At close: Dec 2, 2024, 1:30 PM CST
TPE:6919 Revenue
Caliway Biopharmaceuticals had revenue of 40.47M TWD in the twelve months ending March 31, 2025, up 3.25% year-over-year. In the year 2024, Caliway Biopharmaceuticals had annual revenue of 44.43M with 14.13% growth.
Revenue (ttm)
40.47M
Revenue Growth
+3.25%
P/S Ratio
2,945.62
Revenue / Employee
n/a
Employees
n/a
Market Cap
119.20B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 11.34B |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 19.12B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Pegavision | 6.69B |
| Lumosa Therapeutics | 43.59M |
| Center Laboratories | 1.62B |